La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Replimune Group Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Replimune Group sono diminuiti a un tasso annuo medio di -33.8%, mentre il settore Biotechs ha visto gli utili crescere a un tasso annuo di 19.1%.

Informazioni chiave

-33.8%

Tasso di crescita degli utili

-21.0%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	-51.6%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

Replimune: In The 'Buy Zone' Again

Oct 01

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Sep 02

Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

May 24

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Apr 30

We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Feb 08

Replimune Group EPS misses by $0.03

Feb 04

Dosing underway in Replimune's early-stage cancer study with gene therapy

Jan 05

Replimune: Interesting Developer Of Oncolytic Immunotherapies

Dec 06

Replimune Group EPS misses by $0.02

Nov 05

Ripartizione dei ricavi e delle spese

Come Replimune Group guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:REPL Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	-220	60	175
31 Mar 24	-216	61	172
31 Dec 23	-210	59	167
30 Sep 23	-199	57	155
30 Jun 23	-182	55	134
31 Mar 23	-174	51	123
31 Dec 22	-157	46	107
30 Sep 22	-147	45	96
30 Jun 22	-133	42	87
31 Mar 22	-118	39	76
31 Dec 21	-108	35	71
30 Sep 21	-100	31	66
30 Jun 21	-91	27	60
31 Mar 21	-81	24	54
31 Dec 20	-75	23	48
30 Sep 20	-70	21	46
30 Jun 20	-61	20	40
31 Mar 20	-53	17	36
31 Dec 19	-43	15	30
30 Sep 19	-35	12	25
30 Jun 19	-30	10	23
31 Mar 19	-31	9	20
31 Dec 18	-31	9	19
30 Sep 18	-28	8	15
30 Jun 18	-26	7	13
31 Mar 18	-20	6	11
31 Dec 17	-17	4	9

Guadagni di qualità: REPL al momento non è redditizia.

Margine di profitto in crescita: REPL al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: REPL non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 33.8% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di REPL nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: REPL non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 0.5% ).

Rendimento del capitale proprio

ROE elevato: REPL ha un Return on Equity negativo ( -51.59% ), in quanto al momento non è redditizio.

Replimune Group Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Chief Business Officer notifies of intention to sell stock

Chief Strategy Officer notifies of intention to sell stock

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates fall by 42%

CEO & Director recently sold US$323k worth of stock

No longer forecast to breakeven

Insufficient new directors

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group, Inc. Announces Executive Appointments

Chief Business Officer exercised options and sold US$360k worth of stock

Price target increased to US$48.89

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune secures $200M term loan

Replimune: Recent Developments Strengthen Bull Thesis

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold US$156k worth of stock

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Chief Operating Officer notifies of intention to sell stock

Replimune: In The 'Buy Zone' Again

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Chief Medical Officer Andrea Pirzkall has left the company

Chief Business Officer exercised options and sold US$587k worth of stock

Chief Operating Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

Forecast to breakeven in 2026

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Chief Operating Officer notifies of intention to sell stock